Kidswell Bio Corporation Logo

Kidswell Bio Corporation

Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.

4584 | T

Overview

Corporate Details

ISIN(s):
JP3386460004
LEI:
Country:
Japan
Address:
中央区新川一丁目2番12号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kidswell Bio Corporation is a biopharmaceutical company focused on the research and development of innovative pharmaceuticals and therapeutics, with a particular emphasis on pediatric diseases. Formerly known as Gene Techno Science and founded in 2001, the company's operations are centered around three core business segments: Biosimilars, leveraging its expertise in cell line development and CMC; New Biologics, which includes the development of novel antibodies for cancer and eye diseases; and Cell Therapy, which pioneers next-generation cellular medicines based on SHED (Stem cells from Human Exfoliated Deciduous teeth) to address unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 07:44
Registration Form
確認書
Japanese 8.1 KB
2025-11-14 07:43
Interim Report
半期報告書-第26期(2025/04/01-2026/03/31)
Japanese 189.9 KB
2025-06-30 08:33
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2025-06-27 08:36
Registration Form
確認書
Japanese 8.0 KB
2025-06-27 08:35
Governance Information
内部統制報告書-第25期(2024/04/01-2025/03/31)
Japanese 22.2 KB
2025-06-27 08:33
Annual Report
有価証券報告書-第25期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2025-03-31 09:16
Regulatory News Service
臨時報告書
Japanese 18.2 KB
2024-12-26 07:56
Registration Form
有価証券届出書(組込方式)
Japanese 543.7 KB
2024-11-14 07:50
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-14 07:47
Interim Report
半期報告書-第25期(2024/04/01-2025/03/31)
Japanese 185.0 KB
2024-06-27 09:12
Post-Annual General Meeting Information
臨時報告書
Japanese 22.5 KB
2024-06-27 09:11
Governance Information
内部統制報告書-第24期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:11
Registration Form
確認書
Japanese 8.1 KB
2024-06-27 09:10
Annual Report
有価証券報告書-第24期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-06-07 08:39
Regulatory News Service
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all Kidswell Bio Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kidswell Bio Corporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kidswell Bio Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea
182400
NLS Pharmaceutics Ltd. Logo
Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.
United States of America
NLSP
NovaBay Pharmaceuticals, Inc. Logo
Develops clinically-proven anti-infective therapies for eyecare, skincare, and wound care.
United States of America
NBY
Novacyt Logo
Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.
France
ALNOV
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland
NOVN
NOVAVAX INC Logo
Develops and commercializes nanoparticle vaccines for serious infectious diseases.
United States of America
NVAX
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea
229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark
NOVO
NRX Pharmaceuticals, Inc. Logo
Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.
United States of America
NRXP
NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA

Talk to a Data Expert

Have a question? We'll get back to you promptly.